



LKT Laboratories, Inc.

GDC-0449

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID G1408

CAS No. 879085-55-9

Chemical Name

Synonym GDC0449, Vismodegib

Formula $C_{19}H_{14}Cl_2N_2O_3S$

Formula Wt. 421.30

Melting Point


Purity $\geq 98\%$

Solubility DMSO 84 mg/mL (199.38 mM)
Water Insoluble
Ethanol Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description GDC-0449 is an inhibitor of Smo that prevents downstream hedgehog (Hh) signaling. GDC-0449 exhibits anticancer chemotherapeutic activity; it is currently approved to treat basal cell carcinoma and is in clinical trials as a potential treatment for other cancers. GDC-0449 inhibits cell motility, invasion, and colony formation in basal cell carcinoma cells.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
G1408	25 mg	\$72.50
G1408	100 mg	\$205.90

References Islam SS, Mokhtari RB, Noman AS, et al. Sonic hedgehog (Shh) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer. Mol Carcinog. 2015 Mar 1. [Epub ahead of print]. PMID: 25728352.

Erdem GU, Sendur MA, Ozdemir NY, et al. A comprehensive review of the role of Hedgehog pathway and Vismodegib in the management of Basal Cell Carcinoma. Curr Med Res Opin. 2015 Feb 17:1-45. PMID: 25690490.

Kim EJ, Sahai V, Abel EV, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res. 2014 Dec 1;20(23):5937-45. PMID: 25278454.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.